-
http://www.pharmaxis.com.au/
Yesterday, Gliontos on H/C referred to:
http://biz.yahoo.com/prnews/050826/to162.html?.v=9
Extract:
Aug. 26: PATCH: "We have enjoyed a phenomenal growth rate from our share ownership in our pharmaceutical investment and we would expect that the value of our investment to receive a significant boost from successful clinical results next week."
Comment: He is referring to PXS. Normally he should'nt be making those remarks.
Patch is the second largest shareholder in PXS.
Topped up at $2.24 this morning. Now $2.32 (+14).
We'll see what these PXS results will be. Thanks Gliontos!
Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.
-
Bronchitol Cystic Fibrosis Trial Results Positive
http://stocknessmonster.com/news-ite...E=ASX&N=380284
Extract:
"Pharmaxis has received Orphan Drug Status from the Food and Drug Administration (FDA) for Bronchitol in cystic fibrosis.
Pharmaxis plans to present additional data from the study at the internationally important 19th Annual North American Cystic Fibrosis Conference to be held in Baltimore, MD in October".
Share price: $2.28
-
$2.68 on the Nasdaq. See what happens here today
Gerry
This arose from last post on previous thread:
Posted - 29/08/2005 : 1:14:50 PM
----------------------------------------------
http://www.pharmaxis.com.au/
Yesterday, Gliontos on H/C referred to:
http://biz.yahoo.com/prnews/050826/to162.html?.v=9
Extract:
Aug. 26: PATCH: "We have enjoyed a phenomenal growth rate from our share ownership in our pharmaceutical investment and we would expect that the value of our investment to receive a significant boost from successful clinical results next week."
Comment: He is referring to PXS. Normally he should'nt be making those remarks.
Patch is the second largest shareholder in PXS.
Topped up at $2.24 this morning. Now $2.32 (+14).
We'll see what these PXS results will be. Thanks Gliontos!
Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.
-
Share price:$2.81 (+21) Turnover: 368k shares.
http://bigcharts.marketwatch.com/jav...XS&time=&freq=
STO=91
At this stage, some care is needed in case it retraces.
Gerry
-
Share price $3.12.
Having bought it for 84 cents on 17 Sept. 2004 (See page 1), it has proven to be an excellent investment, sofar.
Gerry
-
-
Research report from Wilson:
Global Capital Raising to transition to a Global
Speciality Pharmaceutical Company
http://www.pharmaxis.com.au/library/PXS20051005.pdf
Extracts:
"We have increased our valuation of PXS to $488M as the capital raising reduces the risk profile of the company. The additional capital is to be raised via an IPO in the US and a placement n Australia. We believe there is significant upside to our valuation as the company overcomes various clinical, regulatory and commercialisation hurdles.
Our valuation in the next 12-24 months can increase by approximately $333M. Moreover, for each 10% penetration Bronchitol makes into the cystic fibrosis market over and above our current peak share forecast of 20%, our valuation increases by $82M".
"It is important to note that Bronchitol will probably be used in far more indications than we are currently forecasting. The drug clears mucus from lungs in a manner that does not rely on complex biochemical pathways. As such we believe other uses can include treating conditions such as:
o Pneumonia
o Severe lung infections which lead to or are caused by build up of mucus in the lungs.
The above point cannot be emphasised enough. Bronchitol clears mucus from lungs.
This capital raising gives the company the ability to develop the product for a range of other applications, increasing the upside risk to valuation".
To ensure rapid adoption of Aridol in the global market, PXS is conducting 18 international clinical trials around the world. These trials are not paid for by PXS, but PXS receives the intellectual property arising from these investigations.
These trials are typically run by key opinion leaders, keen to determine whether Aridol is effective in the treatment/management of various respiratory diseases/indications. These key opinion leaders would be instrumental in the development of protocols for the use of
Aridol by general practitioners. Of course, the fact that key opinion leaders are conducting these trials, increases our confidence that awareness of the product will lead to rapid adoption of Aridol".
-
-
-
Trading Halt, pending announcement of results from their second international Phase III trial of the patented Bronchitol in patients with cystic fibrosis. Likely to be negative or positive? Fisher Funds appears to have great faith in the ability of this company to deliver - Barramundi (BRM on the NZX) had over 10% of its portfolio in PXS at 31/3/10.
(I was surprised to find that there have been no posts specifically on this thread since the late Gerry was still with us, although PXS has probably been commented on in other threads re Biotechs)
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Reply With Quote
Bookmarks